Information:
Fel:
ID
18588
Beskrivning
A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT Open Label Extension
Nyckelord
Versioner (2)
- 2016-11-02 2016-11-02 -
- 2016-11-11 2016-11-11 -
Uppladdad den
11 november 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Open Label Extension Galafold (migalastat) AT1001-012 NCT01218659
Open Label Extension Galafold (migalastat) AT1001-012 NCT01218659
Similar models
Open Label Extension Galafold (migalastat) AT1001-012 NCT01218659
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Date of visit
Item
Date of visit
date
C1320303 (UMLS CUI [1])
Item
Will the subject continue into Open Label Extension?
integer
C3640652 (UMLS CUI [1])
CL Item
Yes, the subject successfully completed Visit 9/Month 18 and will continue into open label extension. Please proceed to Visit 10/Month 24. (1)
CL Item
No, the subject successfully completed Visit 9/Month 18 but will not continue into open label extension. Please ensure subject completes Visit 14/Month 19 or 31. (2)
CL Item
No, the subject terminated and did not complete Visit 9/Month 18. Please ensure subject completes Visit 14/Month 19 or 31. (3)